Hi guys, Welcome to the Advanced Video Search Engine, and you are watching Recent advances in gastrointestinal research: DESTINY-Gastric01 and Spotlight. That video is uploaded by VJOncology at 2020-09-29T04:11:17-07:00. We are promoting this video only for entertainment and educational purpose only. So, I hope you like & enjoy it. [nJhZaJrEuTE]
| Name | Recent advances in gastrointestinal research: DESTINY-Gastric01 and Spotlight |
| Video Uploader | Video From VJOncology |
| Upload Date | This Video Uploaded At 29-09-2020 11:11:17 |
| Video Discription | Elizabeth C. Smyth, MD, Cambridge University Hospitals NHS Foundation Trust, discusses developments in clinical research for gastric and colon cancer. Recent trials have shown great results and will influence first-line treatment. However, more research is needed to focus on tumors that are less immunogenic. The Phase II trial DESTINY-Gastric01 (NCT03329690) shows promise with 51% of participants responding to trastuzumab deruxtecan for HER2+ gastric cancer. Finally, the Spotlight trial (NCT03504397), investigating zolbetuximab plus mFOLFOX6 in gastric and gastroesophageal junction cancer, had positive results in the Phase II trial and is now recruiting for Phase III. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology). nJhZaJrEuTE |
| Category | Education |
| Tags | Speaker: Elizabeth C. Smyth | Institution: Cambridge University Hospitals NHS Foundation Trust | Event: VJVirtual | Event: ESMO 2020 | Format: Interview | Subject: Gastrointestinal Cancer | Subject: Colon Cancer | Subject: Gastroesophageal Cancer | Field: Trial Updates | Medicines: Trastuzumab deruxtecan | Medicines: Zolbetuximab | Trial: DESTINY-Gastric01 | Trial: Spotlight | NCT03329690 | NCT03504397 | minimal residual disease | Field: Immuno-Oncology | Field: Treatment |
